Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in Europe
02 Maggio 2024 - 5:30PM
Extended contract now covers a total of 11
European countries
Crossject will receive milestone payments of up
to €1 million in total, upon marketing authorizations
Crossject will sell ZEPIZURE® to the partner with
a markup that is a share of the gross margin
Dijon, France May 02, 2024 -530 pm CET
-- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty
pharma company developing needle-free auto-injectors for emergency
situations, announces it has extended the geographic
coverage of its 22nd December 2023 commercialization agreement
with an undisclosed partner for its innovative rescue therapy for
epileptic seizures ZEPIZURE®, previously known as ZENEO®
Midazolam.
The extended contract now covers a total of 11 European
countries.
As a reminder, under the terms of the agreement, Crossject will
receive milestone payments of up to €1 million in total, upon
marketing authorizations granted in the territories. Crossject will
sell ZEPIZURE® to the partner with a markup that is a share of the
gross margin (net sales from the partner into the markets minus
cost of goods).
Crossject covers regulatory development costs and owns potential
marketing authorizations, while Crossject’s partner controls and is
responsible for all commercial costs.
Crossject had a previous agreement for Germany executed in June
2019 that was terminated without any claim.
About Crossject
Crossject SA (Euronext: ALCJ;
www.crossject.com) is an emerging specialty pharma company. It is
in advanced regulatory development for ZEPIZURE®, an epileptic
rescue therapy previously known as ZENEO® Midazolam, for which it
was awarded a $60 million contract with the U.S. Biomedical
Advanced Research and Development Authority (BARDA). ZEPIZURE® is
based on the Company’s award-winning needle-free autoinjector
ZENEO®, designed to enable patients and untrained caregivers to
easily and instantly deliver emergency medication via intramuscular
injection on bare skin or even through clothing. The Company’s
other products in development include rescue therapies for allergic
shocks, adrenal insufficiencies, opioid overdose and asthma
attacks.
For further information, please contact:
Investors Natasha DrapeauCohesion Bureau+41 76 823
75 27natasha.drapeau@cohesionbureau.com |
MediaSophie BaumontCohesion Bureau+33 6 27 74 74
49sophie.baumont@cohesionbureau.com |
|
- 2024-05- 02- Crossject_Press release_Extension_EN
Grafico Azioni Crossject (EU:ALCJ)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Crossject (EU:ALCJ)
Storico
Da Giu 2023 a Giu 2024